{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-24-000023","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.753727+00:00","generated_at":"2026-06-05T18:38:06.339451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%","bullets":["Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.","Thrombectomy product revenue $190.8M in Q4 (+42.4%); full-year $677.3M (+32.5%).","Net income $54.2M in Q4; adjusted EBITDA margin 18.8%; cash and investments up $40.3M.","FY 2024 guidance: total revenue growth 16-20%, US thrombectomy growth 27-30%, gross margin +100-150bps.","Non-GAAP operating income $37.4M in Q4; full-year $101.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-24-000023","json":"https://secwatch.observer/filing/0001321732-24-000023.json","markdown":"https://secwatch.observer/filing/0001321732-24-000023.md","text":"https://secwatch.observer/filing/0001321732-24-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/0001321732-24-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/pen-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:38:06.339451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5424e3db175cc24a9b95e5dd95d02643e1736dfb","claim":"Penumbra Inc reported the fourth quarter and full year ended December 31, 2023 results: revenue $284.7 million, net income $54.2 million. Guidance reaffirmed.","evidence_excerpt":"company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: • Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency 1 compared to the fourth quarter of 2022. Revenue of $1,058.5 million for the full year 2023,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1321732/000132173224000023/0001321732-24-000023-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$284.7 million"},{"label":"Net income","value":"$54.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}